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Introduction
The development of structure-based vaccinology using well- 
defined subunit antigens has enabled the development of vaccines 
with excellent safety profiles, but this increase in safety has been 
accompanied by a decrease in immunogenicity compared with 
traditional live-attenuated vaccines. Thus, adjuvants have become 
essential components of vaccine formulations in order to promote 
durable and effective immune responses to subunit vaccines 
(1–3). Traditional adjuvants, such as aluminum salts and water/
oil emulsions, have set the standard for safety and efficacy in vac-
cine development but fail to elicit effective immune responses 
to many candidate antigens, and diverse new adjuvant formula-
tions have been pursued in both academic and industrial vaccine 
research (4). Advances in our understanding of innate immunity 
have enabled the identification of new danger-sensing receptors 
relevant for the design of molecular adjuvants acting on defined 
innate immune signaling pathways. In particular, pattern rec-
ognition receptors (PRRs) are key sensors of the innate immune 
system whose role is to identify pathogenic microorganisms and 
promote appropriate immune responses. The most-studied PRRs 
so far are the TLRs, and monophosphoryl lipid A (MPLA), a deriv-
ative of lipopolysaccharide that binds TLR4, is the first example 
of a molecular adjuvant targeting a defined PRR approved for use 
in human vaccines (5). The development of immunomodulators 
capable of stimulating additional PRR pathways offers the possi-
bility of tuning immune responses to achieve appropriate protec-
tive immune responses to poorly immunogenic subunit antigens.
Recently, much attention has focused on cytosolic danger sen-
sors and, particularly, the cytosolic nucleotide sensor stimulator 
of IFN genes (STING). STING, which localizes to the endoplasmic 
reticulum, is a potent inducer of type I IFNs in response to sensing 
cyclic dinucleotides (CDNs) (6). The CDNs recognized by STING 
are small-molecule second messengers used by all phyla of bacte-
ria (7) and are also produced as endogenous products of the cyto-
solic DNA sensor cyclic GMP-AMP synthase (8–10). The canon-
ical bacterial CDN, cyclic di-GMP (cdGMP), has been shown to 
directly bind STING and subsequently initiate IRF3- and NF-κB–
dependent immune responses (11–13).
In parallel to these structural and molecular biology studies 
defining the pathways by which CDNs stimulate innate immu-
nity, chemically synthesized CDNs, including cdGMP, cyclic 
di–inosine monophosphate, and cyclic di-AMP, are beginning 
to be explored as possible adjuvants for subunit vaccines, with 
particular success in promoting mucosal immunity to intranasal 
vaccines (6, 14–16). While these early studies point to the poten-
tial of CDNs as adjuvants promoting both T cell and humoral 
responses to subunit vaccines, the potency of STING agonists 
as parenteral adjuvants for systemic immunity remains unclear. 
For example, while vaccines administered with modest doses of 
cdGMP (5 μg) have been reported to elicit substantial antibody 
titers in response to highly immunogenic model antigens, such 
as ovalbumin (OVA) or β-galactosidase (15, 17, 18), this same 
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Results
Lipid nanoparticles concentrate cdGMP in LN APCs. In preliminary 
studies, we confirmed that, as reported for other antigens (19, 20), 
modest doses (5 μg) of cdGMP administered with weakly immu-
nogenic proteins (e.g., HIV gp120) or low doses of highly immuno-
genic antigens like OVA were ineffective for adjuvanting humoral 
responses above those of protein alone following parenteral immu-
nization (data not shown). To determine whether this lack of effi-
cacy reflected insufficient transport of CDNs to dLNs, we assessed 
LN accumulation of cdGMP following s.c. injection, using a fluoro-
phore-conjugated derivative to enable detection of cdGMP in the 
tissue. As shown in Figure 1A, CDN levels in the dLNs remained 
<4 ng/mg tissue at all time points after injection of unformulated 
cdGMP. By flow cytometry, cdGMP fluorescence was undetect-
able above background in B220+ B cells, CD11c+CD8α+ DCs, or 
CD11c+CD8α– DCs and only found in 2.1% ± 2.6% of macro-
phages (identified as NK1.1–CD11c–CD11b+Ly6G–SSClo cells, ref. 
39 and Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI79915DS1) from inguinal 
or axillary LNs (Figure 1, B and C). Inefficient capture of cdGMP 
in the LNs is consistent with the low molecular weight of CDNs, 
which will be capable of absorption directly into blood capillaries 
at the injection site. Indeed, measurement of cdGMP in the blood 
showed rapid systemic dissemination of the soluble CDN follow-
ing injection (Figure 1A).
Both the potency and safety of CDNs as candidate adjuvant 
compounds should be enhanced by concentration in local lymphoid 
tissues. We thus developed a liposomal nanoparticle formulation of 
cdGMP to enhance the delivery of these compounds to lymphatics 
and promote their capture in dLNs by APCs. cdGMP was encapsu-
lated in 150 nm phosphatidylcholine liposomes containing 5 mol% 
of a PEGylated lipid; PEG reduces nonspecific interactions of the 
vesicles with serum proteins/matrix, enabling better retention of 
encapsulated drugs (40), and modestly enhances lymphatic uptake 
of liposomes (41, 42). PEGylated lipid nanoparticles loaded with flu-
orescently labeled cdGMP were relatively stable in serum, releasing 
only 4% of the encapsulated CDN when incubated in the presence 
of 10% serum at 37°C for 3 days (Figure 1D). In vitro, DCs internal-
ized cdGMP in soluble or nanoparticle forms to equivalently high 
levels (Figure 1E). However, in contrast to the results with free 
CDN, s.c. injection of nanoparticle-cdGMP (NP-cdGMP) led to 
substantial accumulation of the STING agonist in the dLNs, peak-
ing at approximately 60 ng/mg tissue at 24 hours (15-fold greater 
than unformulated CDN) and slowly decaying over the subsequent 
2 days (Figure 1A). At 24 hours after injection, particle-delivered 
cdGMP was detected in approximately 8% of LN macrophages and 
3% to 4% of CD8α– and CD8α+ DCs, but with little uptake observed 
in B cells (Figure 1, B and C). To track the kinetics of lipid nanopar-
ticle uptake by DCs over time, we encapsulated fluorescent OVA 
(OVAAF647) in the particles as a bright tracer, coinjected a 50:50 mix-
ture of NP-cdGMP and NP-OVAAF647, and analyzed the frequency of 
NP-OVAAF647+ cells in dLNs over time. As shown in Figure 1F, the fre-
quency of NP+CD8α+ DCs remained relatively constant over 2 days, 
but NP+CD8α– DCs continued to increase in frequency to a peak of 
approximately 8% at 48 hours before decaying. Coincident with 
increased delivery to LNs, nanoparticle delivery of cdGMP blocked 
dissemination of cdGMP into the systemic circulation (Figure 1A).
dose of cdGMP administered with hemagglutinin protein as a 
clinically relevant influenza antigen was completely ineffective 
as a parenteral vaccine (19). Similarly, cdGMP administered 
s.c. with HIV pseudovirions was also ineffective at adjuvanting 
humoral responses against the HIV Env protein (20). Karaolis 
and colleagues reported that parenteral (i.m.) vaccination with 
cdGMP adjuvanted humoral responses to the Staphylococcus 
aureus clumping factor A antigen, but much higher doses of CDN 
(145 μg) were used (21). Parenteral immunization with 70 to 
290 μg cdGMP and hepatitis B surface antigen similarly elicited 
robust humoral responses, but this response was also accompa-
nied by substantial inflammatory cytokine and chemokine pro-
duction in the systemic circulation 24 hours after immunization 
(22). Such systemic inflammatory signatures are problematic for 
prophylactic vaccines and are likely due to systemic dissemina-
tion of these low-molecular-weight adjuvants, as has been seen 
with other small-molecule adjuvants, such as resiquimod (R848) 
(23). Altogether, these reports suggest that CDNs may be effec-
tive adjuvants for weakly immunogenic antigens but that finding 
an acceptable balance between potency and toxicity may be chal-
lenging for unformulated CDNs (24).
An effective strategy to simultaneously enhance the potency 
and safety of molecular adjuvants is to formulate these com-
pounds in carriers such as nanoparticles. Nanoparticle vehicles, 
such as polymer particles or liposomes, can promote adjuvant 
transport through lymphatics to draining lymph nodes (dLNs), 
while blocking dissemination into the systemic circulation (25, 
26). Concentration of molecular adjuvants in lymph nodes (LNs) 
using nanoparticle carriers can enable profound dose sparing of 
molecular adjuvants, and this approach has been demonstrated for 
a number of TLR agonists, including MPLA, CpG DNA, poly(I:C), 
and small-molecule TLR7/8 compounds (27–33). Importantly, a 
number of TLR agonist-carrying particle formulations have been 
demonstrated to effectively adjuvant the immune response when 
simply admixed with particulate or soluble antigen, i.e., without 
requiring coincorporation of antigen and adjuvant together in 
particles (32, 34–36). Liposomal and oil-based nanoparticle emul-
sions carrying TLR agonists have also been shown to be effective 
in early-stage clinical trials (5, 37, 38).
Motivated by these findings, here we tested the hypothesis 
that concentration of CDNs within lymphoid tissues through the 
use of a nanoparticle carrier could both enhance their relative 
potency and decrease systemic inflammatory side effects, pro-
viding a means to exploit STING signaling for enhanced cellular 
and humoral immunity without toxicity. Using a liposomal nano-
particle formulation of cdGMP, we found that efficient lymphatic 
delivery of CDNs has a broad impact on both innate and adaptive 
immune responses, including potent activation of antigen-pre-
senting cells (APCs), expansion of vaccine-specific helper T cells, 
and robust induction of germinal center B cell differentiation. 
These cellular responses to nanoparticle-CDN vaccination cor-
related with strong and durable vaccine-specific antibody induc-
tion equivalent to approximately 30-fold higher doses of soluble 
CDNs, without the systemic inflammatory toxicity of the latter. 
These enhancements in humoral immunity achieved by nanopar-
ticle-delivered CDN adjuvants were dependent on TNF-α signal-
ing but not type I IFNs.
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on days 6, 13, and 20 with 10 μg OVA with or without 5 μg cdGMP. 
On day 19, the frequency of circulating OVA-specific CD8+ T cells 
was measured by flow cytometry analysis of SIINFEKL peptide/
MHC tetramer–binding cells among PBMCs. NP-cdGMP vaccines 
induced nearly 3-fold higher frequencies of antigen-specific CD8+ 
T cell responses compared with soluble cdGMP (Figure 2, B and 
C). More strikingly, while soluble cdGMP–adjuvanted vaccines had 
little impact on tumor growth or animal survival, NP-cdGMP vac-
cination controlled tumor growth and induced greatly prolonged 
survival, as shown in Figure 2, D and E. To test a more aggressive 
tumor model with a vaccine targeting a tumor-associated antigen, 
animals were inoculated with B16F10 melanoma cells s.c. and 
vaccinated 3 times, beginning on day 5, with a gp100 lipopeptide 
(46) adjuvanted by soluble or nanoparticle cdGMP. NP-cdGMP 
enhanced the frequency of gp100-specific CD8+ T cells by 7-fold 
compared with soluble cdGMP vaccines, delayed tumor growth, 
and prolonged animal survival (Supplemental Figure 3).
NP-cdGMP induces type I IFN directly in LNs and elicits greater 
APC activation than soluble CDN. To determine the impact of 
NP-cdGMP is a potent immunotherapeutic adjuvant. cdGMP 
has been reported to have antitumor activity in murine cancer 
models (43, 44), likely due to the ability of type I IFN to enhance 
CD8+ T cell responses during cross-priming (45). To first measure 
the impact of nanoparticle delivery on T cell priming, C57BL/6 
mice were immunized with OVA protein alone or adjuvanted by 
5 μg cdGMP in soluble or nanoparticle form. Intracellular cytokine 
staining was performed at 7 days after boost on peripheral blood 
mononuclear cells (PBMCs) restimulated with the immunodom-
inant CD4+ and CD8+ T cell epitopes from OVA to identify cyto-
kine-producing antigen-specific T cells. NP-cdGMP–adjuvanted 
vaccines induced 4-fold and 3-fold greater total cytokine+ CD8+ 
and CD4+ T cell frequencies, respectively, compared with vacci-
nation with soluble CDN adjuvant, and increased the frequency 
of polyfunctional (IFN-γ+TNF-α+) cells by 5-fold (Figure 2A). To 
assess the functional efficacy of these T cell responses in a ther-
apeutic setting, we tested the capacity of NP-cdGMP to promote 
antitumor immunity against OVA- or self-antigen–expressing 
tumors. Mice with established EG.7-OVA tumors were vaccinated 
Figure 1. NP-cdGMP enhances LN uptake of CDNs. (A) Groups of BALB/c mice were injected with cdGMPDY547. The presence of CDN in dLNs (2 μg cdGMPDY547 
per mouse, n = 3 per group) and sera of these animals (5 μg cdGMPDY547 per mouse, n = 5 per group) was traced by fluorescence spectroscopy. (B) Repre-
sentative flow cytometry plots of CDN fluorescence in APCs 24 hours following s.c. injection of 2 μg cdGMPDY547 or NP-cdGMPDY547. (C) Mean percentages 
of cdGMPDY547
+ APCs in inguinal or axillary LNs at 24 hours after immunization of NP-cdGMPDY547 or soluble cdGMPDY547 (n = 3 per group). *P < 0.05, ANOVA 
followed by Tukey’s multiple comparison test. (D) Kinetics of cdGMPDY547 release from nanoparticles incubated in PBS containing 10% serum at 37°C. (E) 
Representative images of DC2.4 cells after 2-hour incubations with NP-cdGMPDY547 or soluble cdGMPDY547. Scale bar: 50 μm. (F) Percentage OVAAF647+ DCs 
over time following injection of NP-cdGMP and NP-OVAAF647 (n = 4 per group).
The Journal of Clinical Investigation   T e c h n i c a l  a d v a n c e
2 5 3 5jci.org   Volume 125   Number 6   June 2015
CD69 were also upregulated 
on a large proportion of B cells 
following NP-cdGMP immu-
nization, while soluble cdGMP 
induced these activation mark-
ers on a minority of these cells 
(Figure 3D). Tracking the fre-
quencies of CD86+ APCs over 
time revealed distinct dynam-
ics for APC activation induced 
by soluble versus nanoparticle 
cdGMP: DC activation was low 
and peaked at 48 hours follow-
ing NP-MPER vaccination with 
soluble cdGMP as adjuvant. 
By contrast, vaccination with 
NP-cdGMP as adjuvant elicited 
approximately 4-fold higher 
frequencies of activated DCs, 
which remained elevated for 48 
hours before decaying toward 
baseline (Figure 3E). In addi-
tion, the peak frequency of mac-
rophage activation was 3-fold 
higher after NP-cdGMP–adju-
vanted vaccination than after 
soluble cdGMP–adjuvanted 
vaccination. As expected, non-
adjuvanted NP-MPER vaccines 
elicited lower frequencies of 
activated APCs than either of 
the cdGMP-adjuvanted groups.
The induction of activa-
tion markers on a majority of 
LN APCs following NP-cdGMP 
immunization indicated that 
many more APCs were acti-
vated than directly acquired cdGMP, indicating strong in trans 
activation of B cells and DCs by cdGMP+ cells. To distinguish 
between direct action of CDNs locally in dLNs and stimulation 
of LNs remotely via cytokines produced at the vaccine injection 
site, we evaluated the expression of IFN-β, a signature product of 
STING activation by cdGMP (51, 52). RT-PCR analysis of dLNs 
showed that immunization with NP-MPER and NP-cdGMP 
induced robust expression of both Ifnb1 and its downstream 
gene target Rsad2 that peaked 20 hours after injection, reaching 
35-fold higher levels relative to soluble cdGMP vaccination (Fig-
ure 3F). Nonadjuvanted vaccines showed minimal IFN-β expres-
sion at all time points studied. Thus, concentration of CDNs in 
LNs by nanoparticle delivery induced a much greater frequency 
of activated APCs and higher expression of activation markers 
on a per-cell basis compared with vaccination with unformulated 
CDNs, which correlated with evidence for direct activation of 
type I IFN expression in LNs by the nanoparticle formulation.
Nanoparticle delivery of cdGMP enhances expansion of helper 
T cells and promotes germinal center induction. Follicular helper T 
cells (Tfh cells) provide critical signals to germinal center B cells 
enhanced LN delivery on APC activation and humoral immune 
responses, we evaluated CDNs as adjuvants for a poorly immu-
nogenic vaccine antigen, the membrane proximal external region 
(MPER) from HIV gp41. The MPER antigen, which as part of the 
HIV envelope trimer is thought to reside in juxtaposition to the 
viral membrane (47, 48), was formulated as a palmitoyl-anchored 
peptide displayed on the surface of liposomes that also contained 
a helper epitope derived from gp120 (denoted herein as HIV30; 
ref. 49) tethered by PEG to the inner leaflet of the vesicles (Figure 
3A). We have previously shown that this nanoparticle MPER for-
mulation (NP-MPER) elicits extremely weak anti-MPER humoral 
responses in the absence of coadministered molecular adjuvants 
(50). Thus, we compared NP-MPER vaccines adjuvanted with sol-
uble cdGMP or NP-cdGMP (Figure 3A).
We first assessed the activation of APCs in dLNs after 
cdGMP/NP-MPER immunizations. Twenty hours after vacci-
nation with NP-MPER and NP-cdGMP, both CD86 and MHC-II 
were strongly upregulated on CD8α+ and CD8α– DCs (Figure 3, 
B and C), while vaccination with NP-MPER and soluble cdGMP 
elicited much weaker CD86 and MHC-II expression. CD86 and 
Figure 2. NP-cdGMP promotes potent CD8+ T cell responses and therapeutic antitumor immunity. (A) C57BL/6 
mice were immunized with 10 μg OVA alone or OVA mixed with 5 μg cdGMP or 5 μg NP-cdGMP on days 0 and 14. 
On day 21, PBMCs were restimulated ex vivo with immunodominant CD4+ and CD8+ OVA epitopes and analyzed by 
flow cytometry for intracellular cytokine staining. Mean single- and double-cytokine+ cell frequencies from each 
group are shown. (B–E) C57BL/6 mice (n = 10 per group) were inoculated with 1 × 106 EG.7-OVA cells s.c. on day 0 
and then vaccinated with 10 μg OVA alone or OVA mixed with 5 μg cdGMP or 5 μg NP-cdGMP on days 6, 13, and 20. 
(B) Representative flow cytometry plots. (C) Mean percentages of SIINFEKL-tetramer+ CD8+ T cells on day 19. (D) 
Tumor size over time (compared with OVA alone). (E) Survival over time. **P < 0.01; ***P < 0.001; ****P < 0.0001, 
1-way ANOVA (C), t test (D), and log-rank Mantel-Cox test (E).
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unadjuvanted liposomes. By contrast, vaccination with NP-MPER/
OT-II and NP-cdGMP induced a substantial expansion of the 
transferred OVA-specific T cells, with 5.1-fold more OT-II+ cells 
recovered on day 7 compared with soluble cdGMP–adjuvanted 
vaccines (Figure 4, A and B). The greater increase in T cell expan-
sion for NP-cdGMP seen in total cell counts compared with cell 
frequencies was a result of substantially greater LN swelling and 
total LN cell numbers in NP-cdGMP–vaccinated mice (data not 
shown). The frequency of antigen-specific T cells differentiating 
to a CXCR5+PD-1+ follicular helper phenotype was only slightly 
greater for NP-cdGMP– vs. soluble cdGMP–adjuvanted vaccines 
(Figure 4C), but the much greater overall expansion of the antigen- 
specific T cell population after administration of the former vac-
in support of humoral immunity (53). To test the impact of cdGMP 
adjuvants on the expansion of vaccine-specific helper T cells and 
Tfh cell differentiation, we used an adoptive transfer model using 
OVA-specific OT-II TCR-transgenic CD4+ T cells and liposomal 
MPER vaccines, incorporating the OT-II cognate peptide antigen 
instead of HIV30 as a helper epitope. CD90.1+ OT-II CD4+ T cells 
were adoptively transferred into C57BL/6 recipients, which were 
immunized 24 hours later with NP-MPER vaccines carrying the 
OT-II epitope with or without addition of cdGMP or NP-cdGMP. 
One week after immunization, animals were sacrificed for flow 
cytometry analysis. As shown in Figure 4A, immunization with 
liposomes lacking T helper peptide or using soluble cdGMP adju-
vant failed to significantly expand OT-II+ cells compared with 
Figure 3. NP-cdGMP potently activates APCs. (A) Schematic of NP-MPER and NP-cdGMP vaccine. TCEP, Tris [2-carboxyethyl] phosphine. (B–F) BALB/c 
mice (n = 4 per group) were immunized with NP-MPER alone, NP-MPER plus 5 μg cdGMP, or NP-MPER plus 5 μg NP-cdGMP, and dLNs were collected 20, 
42, or 68 hours later for analysis. (B) Representative flow cytometry data for CD86 and MHC-II expression on CD8α+CD11c+ cells, (C) CD8α–CD11c+ cells, and 
(D) B220+ B cells. Gates are annotated with mean frequency ± SD for each group. (E) Percentage CD86+ APC populations as a function of time. Representa-
tive data from 1 of 2 independent experiments are shown. (F) Expression levels of Ifnb and Rsad2 over time in dLNs, as determined by RT-PCR.
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cines led to 5.3-fold more OT-II Tfh cells (Figure 4D). In parallel, 
we assessed endogenous T cell responses to NP-MPER/OT-II and 
CDN vaccines in C57BL/6 mice (with no adoptive transfers). Sple-
nocytes from all of the vaccine groups that received helper peptide 
produced IL-4 and IL-5 when restimulated with OT-II peptide ex 
vivo, but only animals vaccinated with NP-cdGMP as adjuvant 
also produced IFN-γ and TNF-α (Figure 4E).
Given the enhanced expansion of follicular helper cells stimu-
lated by NP-cdGMP, we next examined B cell differentiation and 
germinal center induction following CDN-adjuvanted immuni-
zations. Groups of mice were immunized with NP-MPER with or 
without cdGMP adjuvants, and 8 days after immunization, B cell 
differentiation in dLNs was analyzed via flow cytometry. None of 
these primary NP-MPER immunizations induced substantial plas-
mablast differentiation (Figure 5, A and B). However, germinal 
center induction was strongly affected by NP-cdGMP adjuvants; 
mice that received NP-MPER and NP-cdGMP immunization 
showed greatly increased numbers of PNA+GL-7+ germinal center 
B cells (Figure 5, C and D).
cdGMP nanoparticles promote strong humoral responses, while 
avoiding systemic cytokine induction. To confirm that cdGMP 
acts in a STING-dependent manner when delivered in nano-
particles, wild-type (C57BL6/J) or STING-deficient (C57BL/6J- 
Tmem173gt/J, golden ticket mutation) mice (54) were immunized 
with NP-MPER and NP-cdGMP. As expected, MPER-specific 
antibody responses promoted by NP-cdGMP were dependent on 
the presence of STING (Figure 6A). To determine the impact of 
enhanced helper T cell expansion and germinal center induction 
by NP-cdGMP on the humoral immune response, we next assessed 
antibody titers elicited by CDN-adjuvanted vaccines. To address 
relative potency of the soluble and formulated CDNs, NP-MPER 
vaccines were administered as a prime and boost with 5 μg NP- 
cdGMP and compared with vaccines adjuvanted by soluble cdGMP 
in doses ranging from 5 to 150 μg. NP-cdGMP–adjuvanted vac-
Figure 4. NP-cdGMP promotes antigen-specific CD4+ T cell expansion. (A–D) C57BL/6 mice (n = 4 per group) received adoptive transfer of 105 CD90.1+ OT-II 
CD4 T cells and were immunized 24 hours later with NP-MPER with or without the OT-II helper epitope and with or without addition of cdGMP or NP- 
cdGMP. One week later, OT-II T cell responses were characterized via flow cytometry. (A and C) Representative flow cytometry plots and (B and D) total cell 
counts of total CD90.1+ OT-II T cells and CXCR5+PD-1+ OT-II cells, respectively. Data are combined from two independent experiments (in total n = 8 mice per 
group). (E) C57BL/6 mice (n = 3 per group) without OT-II adoptive transfer were immunized were immunized as in A on days 0, 21, and 42, and on day 49 
splenocytes were restimulated for 48 hours with OT-II peptide or media only, and supernatants were assessed for cytokines by bead-based ELISA.  
*P < 0.05; **P < 0.01; ***P < 0.001, ANOVA followed by Tukey’s multiple comparison test (B and D) and Bonferroni’s multiple comparison test (E).
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cines elicited 8.2-fold higher levels of total anti-MPER serum IgG 
than the equivalent soluble cdGMP dosage, and 50% of animals 
immunized with soluble cdGMP failed to mount any detectable 
IgG response at this dose of cdGMP (Figure 6B). NP-cdGMP sim-
ilarly elicited enhanced MPER-specific IgG1 and IgG3 responses. 
Increasing the dose of unformulated cdGMP led to increasing 
MPER-specific IgG responses, but only the highest dose of soluble 
cdGMP (150 μg) elicited antibody titers comparable to the nano-
particle CDN formulation (Figure 6B). However, measurement 
of serum inflammatory cytokines 6 hours after immunization 
revealed that this roughly equipotent dose of soluble cdGMP elic-
ited much higher levels of systemic IL-6, TNF-α, and IFN-β than 
NP-cdGMP immunization (Figure 6C), with the latter suggesting 
systemic triggering of STING. Thus, nanoparticle-mediated con-
centrations of cdGMP in LNs enabled robust humoral immune 
responses to a poorly immunogenic vaccine to be achieved, with-
out concomitant induction of systemic inflammatory toxicity.
We next assessed the durability of humoral responses elicited 
by CDN adjuvants and compared their potency to MPLA, a well-
studied and effective adjuvant for humoral immunity representa-
tive of the TLR4 agonist adjuvants in several licensed vaccines (5, 
55). Mice were immunized on days 0, 21, and 42 with NP-MPER 
alone, NP-MPER with coincorporated MPLA, or NP-MPER adju-
vanted by cdGMP or NP-cdGMP. Peak antibody titers 7 days after 
the second boost were 11-fold greater for vaccines adjuvanted 
by NP-cdGMP compared with those adjuvanted by either sol-
uble cdGMP or MPLA (Figure 7A). Antibody isotype analysis 
demonstrated that NP-cdGMP–adjuvanted vaccines consistently 
induced 20- to 100-fold higher MPER-specific IgG1, IgG2A, and 
IgG3 responses compared with soluble cdGMP– or MPLA-adju-
vanted vaccines (Figure 7B). Further, at 4.5 months after priming, 
MPER titers elicited by the MPLA-adjuvanted vaccine had waned 
by 40%, while vaccines administered with NP-cdGMP showed 
no decay in total serum MPER-specific IgG (Figure 7A). Even fol-
lowing two booster immunizations, vaccines adjuvanted by NP- 
cdMGP trended toward higher frequencies of germinal center 
cells in LNs compared with vaccines adjuvanted by NP-MPER/
MPLA or NP-MPER and cdGMP (Figure 7C). Because distinct 
danger signal pathways can act in synergy (56, 57), we also eval-
uated the relative effectiveness of MPER-NP vaccines adju-
vanted with both MPLA and cdGMP. Addition of soluble cdGMP 
to MPLA/MPER-NP vaccines increased their post boost peak 
titer by 5.3-fold, while the addition of NP-cdGMP to the MPLA/
MPER-NP vaccine increased peak anti-MPER IgG responses 
67-fold, a response that remained approximately 10-fold above 
titers elicited by MPLA-only–adjuvanted vaccines for at least 
150 days (Figure 7D). This same trend of enhancement was also 
observed in IgG1, IgG2A, and IgG3 titers at day 49 (Figure 7E). 
Thus, CDNs promoted durable antibody responses, and even 
when compared with another nanoparticle-formulated molecular 
adjuvant (liposomal MPLA), NP-cdGMP elicited 11-fold greater 
steady-state antibody titers, which could be further modestly 
boosted by combining MPLA and CDNs as tandem adjuvants.
CDN targeting to LNs ablates plasmacytoid DCs, but vaccine 
responses are independent of plasmacytoid DCs. Although plasma-
cytoid DCs (pDCs) are both major producers of type I IFN and 
activated by IFNs (58, 59), it is unknown how CDNs affect pDCs 
and whether they play a role in the adjuvant activity of CDNs in 
Figure 5. Primary plasmablast and germinal center formation is enhanced with NP-cdGMP. BALB/c mice (n = 4 per group) were immunized with 
NP-MPER/HIV30 alone or adjuvanted with 5 μg cdGMP or NP-cdGMP. dLNs were collected 8 days after immunization for analysis via flow cytometry. (A) 
Representative flow cytometry plots and (B) frequencies of CD138+B220–CD3ε– plasmablasts. (C) Representative flow cytometry plots and (D) cell counts 
of GL-7+PNA+IgDloB220+ germinal center B cells. (D) Cell counts of germinal center B cells. *P < 0.05; **P < 0.01; ***P < 0.001, ANOVA followed by Tukey’s 
multiple comparison test.
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at day 14 after prime. Using these responses against the helper 
epitope as an early readout of the impact of pDC depletion on 
antibody production, we found that depletion of pDCs also had 
no effect on vaccine-specific antibody titers on day 14 (Figure 8D). 
Thus, pDCs do not appear to play an important role in the adjuvant 
activity of CDNs in the setting of parenteral immunization.
Type I IFN and TNF-α play complementary roles following NP- 
cdGMP vaccination. The discordance between the frequency of 
APCs directly taking up NP-cdGMP and the extent of APC acti-
vation elicited by this adjuvant suggests that cytokine signaling 
in trans plays a critical role in the adjuvant activity of CDN nano-
particles. Type I IFNs and TNF-α are major downstream products 
following cdGMP-induced activation of STING (14, 61), and given 
the strong upregulation of IFN-β expression in LNs 20 hours after 
NP-cdGMP immunization, we first examined the role of type I 
IFN in the response to NP-cdGMP immunization. To test the role 
of type I IFN signaling, mice were administered a blocking anti–
IFN-α/β receptor antibody (anti-IFNαR1) or its isotype control 
and then immunized with NP-MPER and NP-cdGMP. Twenty-
four hours after immunization, animals treated with anti-IFNαR1 
showed greatly reduced frequencies of CD86+ B cells, macro-
phages, CD8α+ DCs, and CD8α– DCs relative to the isotype control 
group (Figure 9A). However, this reduction in early APC activation 
had no influence on early antibody titers against the HIV30 helper 
peptide at day 14 (Figure 9B). Blaauboer et al. previously observed 
that antibody responses to mucosal vaccines adjuvanted with sol-
uble cdGMP were independent of type I IFN but dependent on 
TNF-α (61). Although Blaauboer et al. used Tnfr1–/– mice to demon-
strate the role of this cytokine on the adjuvant action of cdGMP, 
vivo. To investigate how LN targeting of cdGMP affected pDCs, 
mice were immunized with NP-MPER alone or with cdGMP adju-
vants. dLNs were collected 1 day later, and B220+CD11c+PDCA1+ 
pDCs were analyzed by flow cytometry (Supplemental Figure 2A). 
As shown in Figure 8, A and B, all of the immunizations induced 
an early decrease in the number of pDCs in dLNs, but cdGMP 
vaccines induced a remarkable sustained loss of these cells; pDCs 
were almost completely eliminated from dLNs of NP-cdGMP–
immunized animals for several days. Quantification of pDC num-
bers in dLNs revealed that soluble cdGMP and NP-cdGMP rapidly 
induced 3-fold and 11-fold losses of pDCs compared with naive 
animals, respectively (Figure 8B). It has previously been shown 
that pDCs are engaged in an autocrine negative-feedback loop 
with type I IFN: during viral infections, pDCs produce large quan-
tities of IFN, which in turn induces their apoptosis in an autocrine 
manner and transiently depletes these cells (60). However, the 
rapid loss of pDC populations by 20 hours following CDN-adju-
vanted immunization suggests that these cells are not the source 
of the elevated levels of type I IFN expression detected in dLNs at 
this time point (Figure 3F). To confirm that pDCs were not playing 
an important role in the humoral response elicited by CDNs, mice 
were treated with a pDC-depleting antibody (or isotype control; 
Supplemental Figure 2B) and then immunized with NP-MPER 
and NP-cdGMP. Analysis of APC activation in dLNs indicated no 
difference in APC activation in pDC-depleted or control groups 
(Figure 8C). IgG antibody responses to the weakly immunogenic 
MPER peptide are weak to undetectable in the first 2 weeks after 
a single priming immunization, but responses against the HIV30 
helper epitope cocarried by the liposomal vaccine were detectable 
Figure 6. NP-cdGMP promotes robust 
humoral immunity, while minimizing 
systemic cytokine induction. (A) C57BL/6J 
(wild-type) or C57BL/6J-Tmem173gt/J 
(STINGGt/Gt, golden ticket mutation) mice were 
immunized on days 0 and 21 with NP-MPER/
HIV30 plus NP-cdGMP (n = 4 per group). Total 
serum anti-MPER IgG titers were assessed 
by ELISA on day 28. ***P < 0.001, t test. (B 
and C) BALB/c mice (n = 4 per group) were 
immunized on days 0 and 21 with NP-MPER/
HIV30 combined with 5 μg NP-cdGMP (NP) 
or graded doses of soluble cdGMP (sol). (B) 
ELISA analysis of serum anti-MPER IgG, IgG1 
and IgG3 titers at day 28. (C) Serum cytokine 
levels assessed at 6 hours after immuniza-
tion via ELISA. *P < 0.05; **P < 0.01;  
***P < 0.001, ANOVA followed by Turkey’s 
multiple comparison test.
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as mucosal adjuvants. For example, Ebensen et al. first demon-
strated that intranasal administration of soluble antigen and 
cdGMP induced higher antigen-specific serum IgG and mucosal 
IgA when using the model antigen β-galactosidase (15). When 
administered intranasally with the S. pneumonia antigen pneumo-
coccal surface protein A, cdGMP protected against S. pneumonia 
colonization (67). The ability of structurally related CDNs, such as 
cyclic di–inosine monophosphate and cyclic di-AMP, to adjuvant 
mucosal immunizations has also been reported (17, 68).
In contrast to the robust response to CDNs in mucosal immu-
nization, the efficacy of CDNs as adjuvants in the setting of tra-
ditional parenteral immunization has been less clear, with much 
of the early published data focused on the use of CDNs to boost 
immunity against highly immunogenic model antigens and/or 
using large doses of CDNs. As shown here, the limited potency of 
parenterally administered CDNs reflects poor lymphatic uptake of 
these small-molecule immunomodulators; they are instead cleared 
from tissues via the blood. This biodistribution issue is a property of 
molecular size: because blood absorbs approximately 10-fold more 
fluid from tissues than lymph, molecules small enough to permeate 
blood vessels (less than ~1 kDa) tend to show predominant clear-
ance to the blood (69). Therefore, increasing CDN-mediated vac-
cine responses through increased dosing of unformulated CDNs is 
accompanied by parallel increases in systemic inflammatory toxicity. 
This pharmacokinetic behavior is shared by other small-molecule 
we chose to investigate this question by administration of an 
anti–TNF-α blocking antibody, due to the absence of follicular DC 
networks observed in Tnfr1–/– mice (62). Twenty-four hours after 
immunization with NP-MPER and NP-cdGMP, TNF-α–blocked 
mice exhibited marginal impairment in APC activation (Figure 
9C), but at 2 weeks after prime, the TNF-α blockade reduced vac-
cine-specific antibody titers 115-fold (Figure 9D). Thus, cdGMP 
targeted to LNs via nanoparticle delivery acts through type I IFN 
and TNF-α to promote early APC activation and class-switched 
IgG production, respectively.
Discussion
CDNs are a relatively new class of immunomodulatory com-
pounds with the potential to promote protective immunity through 
a unique pathway using the cytosolic danger sensor STING and its 
downstream transcription factors NF-κB and IRF-3 (6, 63). The 
publication of crystal structures demonstrating the structural basis 
for CDN sensing through STING (64, 65) and the identification 
of endogenous CDNs as signaling products produced by cyclic 
GMP-AMP synthase sensing of double-stranded DNA (9, 10, 66) 
have provided both a rationale and mechanistic guidance for the 
development of CDNs as adjuvants acting through type I IFNs and 
NF-κB activation in host cells. Indeed, several laboratories have 
recently demonstrated innate immune stimulatory (14, 22, 61) 
and adjuvant activities (63) with CDNs, particularly when applied 
Figure 7. NP-cdGMP elicits durable class-switched humoral responses and synergizes with MPLA to adjuvant MPER vaccines. (A–C) BALB/c mice were 
immunized on days 0, 21, and 42 with NP-MPER/HIV30 alone, NP-MPER/HIV30/MPLA, or NP-MPER/HIV30 plus cdGMP or NP-cdGMP. (A) Serum anti-
MPER total IgG titers assessed via ELISA on days 49 and 138 (n = 3 per group). *P < 0.05, ANOVA followed by Tukey’s multiple comparison test. (B) ELISA 
analysis of specific isotypes of serum anti-MPER Ig at day 49 (n = 3 per group). ****P < 0.0001, ANOVA followed by Tukey’s multiple comparison test. (C) 
Percentages of PNA+GL-7+IgDloB220+ germinal center B cells (GCs) in dLNs at day 49 (n = 3 per group). *P < 0.05, ANOVA followed by Tukey’s multiple com-
parison test. Data from 1 representative of 2 independent experiments are shown. (D and E) BALB/c mice (n = 4 per group) were immunized on days 0, 21, 
and 42 with NP-MPER/HIV30/MPLA alone or additionally adjuvanted with cdGMP or NP-cdGMP. (D) Serum anti-MPER IgG titers over time and (E) specific 
isotype responses at day 49 assessed via ELISA. P < 0.0001, comparison of NP-MPER/MPLA vs. NP-MPER/MPLA + NP-cdGMP groups over time.  
P < 0.0001, comparison of NP-MPER/MPLA + soluble cdGMP vs. NP-MPER/MPLA + NP-cdGMP over time, ANOVA followed by Tukey’s multiple compari-
son test. **P < 0.01; ***P < 0.001; ****P < 0.0001, ANOVA followed by Tukey’s multiple comparison test. Titer values in B and E show geometric mean  
and 96% confidence interval.
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Type I IFNs are signature downstream products of STING acti-
vation by CDNs in host cells (51, 52), and NP-cdGMP led to direct 
induction of type I IFN and downstream target gene expression 
in the dLNs. By contrast, soluble CDN administration induced no 
type I IFN in the dLNs, implying that its effects on APC activation 
are mediated by inflammatory cytokines produced at the injection 
site acting remotely on draining nodes. Such in trans activation of 
DCs by inflammatory cytokines has been shown to elicit weaker 
priming of T cell responses compared with cis activation of DCs 
directly through pathogen-sensing receptors (77, 78). Direct type I 
IFN induction in LNs by NP-cdGMP correlated with more robust 
upregulation of costimulatory and activation markers on LN 
APCs, which occurred earlier and was more sustained (over ~48 
hours) compared with soluble CDN vaccination. Coincident with 
enhanced APC activation, NP-cdGMP drove a 5-fold increase in 
vaccine-specific CD4+ T cell expansion compared with unformu-
lated CDNs, increased CD8+ T cell responses, and enhanced anti-
tumor immunity in the setting of therapeutic vaccination. Thus, 
nanoparticle delivery of CDNs enhanced both early APC activa-
tion and subsequent T cell responses.
Our subsequent analyses focused on determining the impact of 
nanoparticle CDN delivery on humoral immunity, using a liposo-
mal gp41 peptide as a model poorly immunogenic vaccine anti-
gen. First, we examined the induction of antigen-specific follicular 
helper cells, because type I IFN induction in LNs by NP-cdGMP 
might be expected to drive Tfh differentiation (79). Nanoparticle 
delivery of cdGMP only moderately affected the frequency of CD4+ 
T cells differentiating toward a follicular helper phenotype, but the 
much greater overall expansion of antigen-specific CD4+ T cells by 
NP-cdGMP compared with soluble CDN adjuvants in turn trans-
lated into 5.3-fold more vaccine-specific Tfh cells. In line with their 
expected importance in class switching and germinal center forma-
adjuvant compounds, such as R848 and related imidazoquinoline 
TLR7/8 agonist compounds, muramyl dipeptides that trigger NLRs, 
and RNA oligonucleotide ligands of RIG-I (23, 70, 71). For example, 
parenteral injection of R848 is known to rapidly trigger systemic 
inflammatory cytokines, a phenomenon similar to the systemic sig-
nature observed here for CDNs, and induces transient systemic lym-
phopenia within hours of injection (36, 72). To overcome these issues, 
a number of strategies have been explored to limit systemic exposure 
and/or refocus molecular adjuvant delivery to LNs, including con-
jugating of adjuvant compounds with lipid tails (46, 72, 73), directly 
coupling to large-molecular-weight antigens (74, 75), or encapsulat-
ing in nano/microparticles (27, 30, 32, 36).
Here, we demonstrate that nanoparticle delivery using PEG-
ylated liposomal carriers substantially enhances the potency of 
the canonical CDN cdGMP, eliciting enhanced CD4+ and CD8+ T 
cell responses to protein antigens and high-titer, durable humoral 
responses to a model weakly immunogenic peptide antigen at low 
doses of NP-cdGMP. These responses were only matched by approx-
imately 30-fold higher doses of unformulated CDNs that may not 
be translatable to large animals or humans and that induced sub-
stantial systemic cytokine induction. This increase in potency was 
achieved by 15-fold increased LN NP-cdGMP accumulation relative 
to that after soluble cdGMP injection. NP-cdGMP was avidly pino-
cytosed/endocytosed by DCs in vitro, and despite the fact that these 
PEGylated nanoparticles were not designed to promote delivery of 
CDNs to the cytosol, we observed robust APC activation in vivo. 
However, it has recently been reported that STING is capable of 
sensing CDNs contained within impermeable vacuoles of host cells 
during Chlamydia trachomatis infection, and it is hypothesized that 
the ER wraps around the vacuole, enabling ER-localized STING 
to detect vacuole-entrapped cdGMP (76). Thus, APCs may harbor 
intrinsic mechanisms to sense endosomal CDNs.
Figure 8. NP-cdGMP–adjuvanted vaccine responses are independent of pDCs. (A and B) BALB/c mice (n = 4 per group) were immunized with NP-MPER 
alone or combined with cdGMP adjuvants. (A) Representative flow cytometry plots and (B) total cell counts of PDCA1+CD11c+B220+ pDCs at 24 hours after 
immunization. Gates in A shown mean ± SD percentages of pDCs. Data from 1 representative of 2 independent experiments are shown. (C and D) BALB/c 
mice (n = 4 per group) were treated with pDC-depleting or isotype control antibodies and then immunized with NP-MPER/HIV30 and NP-cdGMP. (C) Mean 
percentage CD86+ APCs at 20 hours after immunization. (D) Vaccine-specific anti-HIV30 antibody responses at 14 days after immunization.
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of clinically approved liposomal drugs (83). A limitation of our 
bench-scale formulation approach was the relatively low CDN 
loading efficiency (~35%). However, more advanced polymer or 
lipid nanoparticle carriers (29, 84) that achieve more efficient 
drug loading and/or lipophilic modifications to CDNs to promote 
liposome association (a strategy used successfully with imidazo-
quinoline adjuvants; ref. 72) can readily be envisioned to circum-
vent this issue. Delivery of PRR agonists as adjuvants has variously 
been reported to require coencapsulation in the same particle as 
the antigen (in cis) (85) or simply simultaneous delivery on sepa-
rate particles (in trans) (32, 36, 86). The ability of NP-cdGMP to 
adjuvant immune responses in trans to particulate antigen pro-
vides flexibility for vaccine production and facilitates inclusion of 
NP-cdGMP into existing vaccine platforms. Although many dan-
ger signals are effective in promoting immune responses in mice, 
type I IFN–inducing adjuvants have shown particular promise in 
nonhuman primate models (87, 88) and humans (89, 90) for pro-
moting superior cellular and humoral immunity. The nanoparti-
cle delivery strategy demonstrated here provides a simple means 
to promote both the safety and efficacy of CDNs as a novel type I 
IFN–promoting adjuvant, with potential relevance to human vac-
cine development. Altogether, these results suggest that LN-tar-
geted CDNs can promote both strong antigen-specific T cell prim-
ing and high-titer, durable antibody responses that outperform the 
strong benchmark adjuvant MPLA, suggesting these compounds 
are of interest for further development as candidate adjuvants.
Methods
Materials. Lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 
1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 1,2- 
dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-distearoyl-sn- 
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)- 
2000] (DSPE-PEG), and 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[PDP(polyethylene glycol)-2000] (DSPE-PEG-PDP) were 
purchased from Avanti Polar Lipids. Solvents, BSA and MPLA (from 
Salmonella enterica serotype minnesota Re 595 catalog L6895), 
tion (53), increased numbers of specific Tfh were accompanied by 
enhanced germinal center B cell differentiation, 11-fold increased 
antigen-specific IgG titers that were dependent on the presence of 
STING, and humoral responses that were more durable than vac-
cines administered with the well-known TLR agonist MPLA. How-
ever, sera from these MPER-immunized animals did not neutralize 
HIV (data not shown), indicating that further structural refinements 
are required for this antigen to elicit antibodies capable of recogniz-
ing the functional stalk of the HIV envelope trimer (50).
The presence of IFN expression, suggesting STING activa-
tion directly in dLNs, led us to explore the source of type I IFNs 
following NP-cdGMP vaccination and to quantify the relative 
importance of the key downstream products of STING activation 
on the observed humoral responses. pDCs are major producers of 
type I IFN, but paradoxically these cells appeared to be strongly 
ablated following immunization with cdGMP. pDC depletion was 
detected by 20 hours after immunization, contemporaneous with 
peak IFN expression, suggesting that these cells are not the source 
of the type I IFN induced by NP-cdGMP. This finding is in agree-
ment with a prior study reporting minimal human pDC activation 
by CDNs (14). In further support of the idea that pDCs do not play 
an important role in the adjuvant function of CDNs, pDC deple-
tion had no impact on either early APC activation or subsequent 
IgG production following NP-cdGMP immunization. While type 
I IFNs are a characteristic product of STING activation, CDNs 
also trigger the production of TNF-α through NF-κB (52, 61). Both 
type I IFN and TNF-α have been shown to be important regula-
tors of humoral immunity (80–82), but a recent study suggested 
that cdGMP applied intranasally adjuvants mucosal immunity in 
an type I IFN–independent, TNF-α–dependent manner (61). Here, 
we found that, following NP-cdGMP vaccination, both pathways 
of STING signaling are involved, with early APC activation depen-
dent on IFN-α signaling and early (day 14) class-switched antibody 
responses dependent on TNF-α.
In the interest of translational relevance, we used a PEG ylated 
liposome formulation with a composition similar in nature to that 
Figure 9. Type I IFN shapes early activation of APCs, while TNF-α is 
critical for IgG production following cdGMP-adjuvanted immuniza-
tion. BALB/c mice (n = 4 per group) were treated with anti-IFNαR1, 
anti–TNF-α, or respective isotype control antibodies and then 
immunized with NP-MPER/HIV30 and NP-cdGMP. (A) Percentages 
of CD86+ APCs in the presence of anti-IFNαR1 or isotype control 
antibody at 24 hours after immunization. Data from 1 representative 
of 2 independent experiments are shown. cDCs, conventional DCs. 
(B) Antigen-specific IgG titers at 14 days after immunization in the 
presence or absence of IFNαR1 blockade. (C) Percentages of CD86+ 
APCs in the presence of anti–TNF-α or isotype control antibody at 
24 hours after immunization. (D) Antigen-specific IgG titers in the 
presence or absence of TNF-α blockade at 14 days after immuniza-
tion. Data from 1 representative of 2 independent experiments are 
shown. *P < 0.05; **P < 0.01; ***P < 0.001, individual t tests.
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Sera were collected via retro-orbital bleeding on a weekly basis for sub-
sequent ELISA-based analyses. For TNF-α blockade experiments, mice 
received 0.5 mg anti–TNF-α antibody (clone XT3.11, Bio X Cell) or IgG1 
isotype control antibody (clone HRPN, Bio X Cell) i.p. at 24 hours and 0.5 
hours prior to immunization, as described previously (81). For IFNαR1 
blockade experiments, mice received 1 mg anti-IFNαR1 antibody (clone 
MAR1-5A3, Bio X cell) or IgG1 isotype control antibody (clone MOPC-21, 
Bio X Cell) i.p. 24 hours prior to immunization, as described previously 
(92). For pDC depletion experiments, mice received 0.5 mg anti-PDCA1 
antibody (clone 120G8, Bio X Cell) or IgG1 isotype control antibody 
(clone HRPN, Bio X Cell) i.p. at 48 hours prior to immunization (93). For 
polyfunctional T cell studies, B6 mice were immunized on days 0 and 
14 with 10 μg OVA with blank PBS, 10 μg soluble cdGMP, or 10 μg NP- 
cdGMP, and PBMCs were collected on day 21 for intracellular cytokine 
staining. For tumor immunotherapy studies, B6 mice were inoculated 
s.c. in the right flank with 2.5 × 105 B16.F10 melanoma cells or 1 × 106 
EG.7-OVA cells on day 0. In the EG.7-OVA model, mice were subse-
quently immunized on days 6, 13, and 20 with 10 μg OVA and blank PBS, 
10 μg soluble cdGMP, or 10 μg NP-cdGMP. In the B16.F10 model, mice 
were immunized on days 5, 12, and 19 with 10 μg amph-gp100 and blank 
PBS, 10 μg soluble cdGMP, or 10 μg NP-cdGMP. Tumor area was mea-
sured via calipers over time, and PBMCs were collected 6 days after the 
second immunization for tetramer staining.
CDN characterization studies. For in vitro CDN release from lipid 
nanoparticles studies, aliquots of cdGMPDY547 liposomes in PBS contain-
ing 10% BSA (dose of 1 μg cdGMPDY547) were placed into 10,000 MWCO 
Slide-A-Lyzer MINI Dialysis units (Thermo Fisher), and each aliquot 
was incubated in reservoirs of 10% BSA in PBS at 37°C. The presence 
of cdGMPDY547 in reservoirs over time was measured (3 samples per time 
point) via fluorescence (excitation 545/emission 584) using a Tecan 
Infinite M200 Pro absorbance/fluorescence plate reader. For in vivo 
studies of LN drainage of CDN, mice were injected s.c. with 100 μl PBS 
(50 μl on each side of the tail base) containing 2 μg cdGMPDY547 either in 
soluble or nanoparticle form. For each mouse, inguinal and axillary LNs 
were subsequently collected (3 mice per time point), pooled together, 
massed, and incubated for 18 hours in 1:25 Liberase TM (Roche) in PBS. 
LNs were then sonicated for 30 seconds at 3 watts output power using a 
Misonix XL-2000 probe sonicator. Following addition of 10% trichloro-
acetic acid in methanol, samples were centrifuged at 18,000 rcf for 15 
minutes. Detection of cdGMPDY547 in supernatants was measured via 
fluorescence (excitation 545/emission 584) using a Tecan Infinite 
M200 Pro absorbance/fluorescence plate reader.
OT-II T cell adoptive transfer and ex vivo restimulation studies. For 
adoptive transfer studies, OT-II+ CD4+ T cells were isolated from 
CD90.1 OT-II B6 mouse splenocytes using an EasySep CD4 T Cell Iso-
lation Kit (StemCell Technologies) and transferred to C57BL/6 recip-
ients by i.v. retro-orbital injection at 1 × 105 cells per mouse. Twenty- 
four hours later, mice were immunized with NP-MPER vaccines con-
taining the DSPE-OT-II helper peptide. Seven days after immuniza-
tion, inguinal and axillary LNs were collected for subsequent analysis 
via flow cytometry. For ex vivo OT-II restimulation studies, B6 mice 
were immunized on days 1, 28, and 42 with OT-II–containing vaccines. 
On day 49, 3 × 105 splenocytes in single-cell suspensions were seeded 
onto 96-well plates with or without 5 μM OT-II peptide and incubated 
for 48 hours, and cytokine levels in supernatants were assessed using 
a Milliplex MAP Mouse Th17 Magnetic Bead Kit from EMD Millipore 
and the Bio-Plex 3D suspension array system from Bio-Rad.
were purchased from Sigma-Aldrich. cdGMP was purchased from 
Invivogen, and cdGMPDY547 was purchased from BIOLOG Life Sci-
ence Institute and dissolved in ddH2O. The CD4+ T cell helper 
peptides OT-II (CKISQAVHAAHAEINEAGREV) and HIV30 
(RRNIIGDIRQAHCNISRAKW) and the MPER peptide (ELDKWASL-
WNWFNITNWLWYIK) were synthesized at the Tufts University Core 
Facility. SIINFEKL peptide was purchased from GenScript. MPER was 
purchased with either an N-terminal biotin (for ELISAs) or a palmitoyl 
tail (for immunizations). For membrane-anchored DSPE-HIV30 and 
DSPE-OT-II conjugates, HIV30 or OT-II were linked to DSPE-PEG-
PDP via the cysteine residue of each peptide by dissolving HIV30 or 
OT-II in DMF with 1.5 equivalents of DSPE-PEG-PDP and agitating at 
25°C for 18 hours. The conjugates were then diluted in 10x deionized 
water, lyophilized into powder, and redissolved in deionized water. 
Peptide concentrations were determined by Direct Detect infrared 
spectroscopy analysis (EMD Millipore). OVA used in the intracellu-
lar cytokine staining and tumor immunotherapy immunizations was 
purchased from Worthington Biochemical Corporation. Cysteine- 
terminated gp100 EGP long (CAVGALEGPRNQDWLGVPRQL) (91) 
was conjugated to DSPE-PEG-2000-maleimide from Laysan Biotech-
nology and purified as previously described (46).
NP-MPER and NP-cdGMP synthesis. A 2:2:1 molar ratio of DMPC/
DOPC/DOPG in chloroform with palm-MPER added at a 1:200 
MPER/lipid mole ratio was dried under nitrogen followed by incu-
bation under vacuum at 25°C for 18 hours. Liposomes incorporating 
MPLA, DSPE-HIV30, or DSPE-OT-II were prepared by including 
these components in the organic solution prior to drying lipid films. 
Lipids were hydrated with pH 7.4 PBS to a final concentration of 26.5 
mM lipid and vortexed 30 seconds every 10 minutes for an hour. The 
resulting NP-MPER vesicles were passed through 6 freeze-thaw cycles 
between liquid nitrogen and a 37°C water bath followed by extrusion 
21 times through 0.2-μm pore polycarbonate membranes (Whatman 
Inc.), respectively. For NP-cdGMP, a 38:38:19:5:0.95 molar ratio of 
DMPC/DOPC/DOPG/DSPE-PEG/cdGMP in chloroform was dried 
under nitrogen followed by incubation under vacuum at 25°C for 
18 hours, and following drying, the resulting lipid/cdGMP films were 
resuspended to a final concentration of 240 μg cdGMP per ml PBS and 
then freeze/thawed and extruded to form 150 nm liposomes. Unen-
capsulated cdGMP was removed by centrifugation of the liposomes 
via Airfuge (Beckman Coulter), and quantification of cdGMP encap-
sulation efficiency was determined by UV absorption at 254 nm. To 
synthesize cdGMPDY547 lipid nanoparticles, cdGMPDY547 was used 
in lieu of cdGMP at the lipid dry-down step. To synthesize fluores-
cently labeled “mock” cdGMP lipid nanoparticles, a dried lipid film of 
DMPC/DOPC/DOPG/DSPE-PEG (at a 38:38:19:5:0.95 molar ratio) 
was rehydrated in 520 μg/ml OVAAF647 (Invitrogen) in PBS (lipid con-
centration = 35.6 mM) and synthesized as before. Dynamic light scat-
tering (using a Wyatt Dyna Pro Plate Reader II) was performed by the 
Swanson Biotechnology Center at the Koch Institute.
Mice and immunizations. BALB/c, C56BL/6 (B6), C57BL/6J- 
Tmem173gt/J (STINGGt/Gt), and CD90.1 OT-II B6 mice were purchased 
from The Jackson Laboratory. Experiments were conducted using 
female mice, 6–8 weeks of age. Groups of mice were immunized with 
100 μl MPER liposomes in PBS (40 μg MPER peptide) s.c. at the tail base, 
50 μl per side. Where indicated, 100 μl soluble or liposomal cdGMP in 
PBS (5 μg cdGMP unless otherwise noted) was administered immedi-
ately following NP-MPER injection, s.c. at the tail base, 50 μl per side. 
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blocked with 1% w/v BSA in PBS (BSA-PBS), washed with 0.05% 
Tween 20 in PBS, incubated for 2 hours with 2 μg/ml biotin-MPER 
in BSA-PBS, washed, and then incubated for 2 hours with serially 
diluted serum samples. Following another washing step, the plates 
were incubated for 90 minutes with HRP-conjugated goat anti-mouse 
IgG (Bio-Rad) in BSA-PBS, washed, and developed with TMB sub-
strate, and absorbance at 450 nm was read on a Tecan Infinite M200 
Pro plate reader. HIV30-specific antibody levels were detected via 
ELISA in a similar manner; plates were directly coated with 100 μg/
ml HIV30, blocked, washed, and incubated with serum and IgG-HRP, 
as described above. Titers were defined as the inverse serum dilution, 
giving an absorbance of 0.3. To determine serum cytokine responses 
after immunization, sera were collected at 6 hours after immuniza-
tion. Levels of IFN-β were detected by the VeriKine-HS Mouse IFN-β 
Serum ELISA Kit (PBL Assay Science), and levels of IFN-γ, TNF-α, and 
IL-6 were determined by the Milliplex MAP Mouse Th17 Magnetic 
Bead Kit (EMD Millipore).
Statistics. Statistical analyses were performed using GraphPad 
Prism software. All values and error bars are mean ± SD except where 
indicated differently. Comparisons of formulations over time used 
2-way ANOVA tests, and comparisons of multiple formulations at a 
single time point were performed using 1-way ANOVA and Tukey’s 
tests. Two-tailed unpaired t tests were used to determine statisti-
cal significance between two experimental groups for all other data, 
unless otherwise noted.
Study approval. Experiments and handling of mice were conducted 
under federal, state, and local guidelines under an IACUC protocol and 
with approval from the Massachusetts Institute of Technology IACUC.
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Antibodies and flow cytometry. For analyses of APCs, inguinal and 
axillary LNs were subjected to enzymatic digestion (Collagenase/
Dispase and DNAse I, Roche) in order to obtain single-cell suspen-
sions as previously described (94). For processing of PBMCs, blood 
was subjected to 2 cycles of ACK lysis buffer incubation and washing 
in PBS. For all other flow cytometric–based analyses of LNs, single-
cell suspensions were obtained by passage of tissues through a 70-μm 
filter (BD Biosciences). Cells were incubated for 15 minutes at 25°C 
with anti-CD16/32 and then for 30 minutes at 25°C with the follow-
ing antibodies (all purchased from eBioscience unless otherwise 
specified): CD4, CD69, CD11c, B220, CD11b, Ly6G, NK1.1, CD8α, 
PDCA1 (eBio927), CD86, and MHC-II for the activation of APCs; 
B220, CD138, CD3, GL-7, IgD, and PNA for germinal center staining; 
CD90.1, CXCR5, CD8α, CD4, B220, and CD44 for OT-II+ CD4+ T cell 
staining; and PE-H-2Kb OVA (SIINFEKL) or PE-H-2Db gp100 (EGS-
RNQDWL) tetramers (MBL International Corporation), CD8-APC, 
and DAPI for antigen-specific CD8+ T cell staining. For intracellular 
cytokine staining, PBMCs were incubated for 6 hours at 37°C with 
OT-II and SIINFEKL peptides at a concentration of 10 μg/ml each. 
Two hours into incubation with peptide, Brefeldin A (eBioscience) was 
added. Cells were surface stained with CD8 and CD4, fixed with Cyto-
fix/Cytoperm (BD Biosciences), and stained intracellularly with IFN-γ 
and TNF-α antibodies. Flow cytometric analysis was carried out using 
a BD Canto or BD Fortessa (BD Biosciences), and analysis of cells was 
performed using FlowJo software (Tree Star Inc.).
Quantitative PCR analysis. LNs were isolated from immunized 
mice, snap frozen in liquid nitrogen, and stored at –80°C for future 
use. Frozen LNs were homogenized, and RNA was isolated using the 
RNeasy Pluse Universal Mini Kit (Qiagen) according to the manu-
facturer’s protocol. Total RNA was extracted using the RNeasy Plus 
Universal Kit (Qiagen) and quantified using a NanoDrop spectro-
photometer (Thermo Fisher). Multiplex primers were designed using 
the PrimeTime qPCR assay (Integrated DNA Technologies). Primer 
sequences are as follows: mouse Ifnb1, (forward) 5′-CGAGCAGA-
GATCTTCAGGAAC-3′ and (reverse) 5′-TCACTACCAGTCCCAG-
AGTC-3′; mouse Rsad2, (forward) 5′-ACACAGCCAAGACATC-
CTTC-3′ and (reverse) 5′-CAAGTATTCACCCCTGTCCTG-3′; and 
mouse Gapdh, (forward) 5′-CTTTGTCAAGCTCATTTCCTGG-3′ and 
(reverse) 5′-TCTTGCTCAGTGTCCTTGC-3′. One-step cDNA synthe-
sis and RT-PCR reactions were set up with 200 ng total RNA using the 
LightCycler 480 RNA Master Hydrolysis Probes Kit (Roche) accord-
ing to manufacturer’s instructions, and analysis was performed on a 
Roche LightCycler 480 II real-time system.
Plate- and bead-based ELISAs. MPER-specific antibody levels were 
detected by ELISA: 96-well Nunc Polysorp plates (ThermoFisher) 
were coated with 25 μg/ml streptavidin (Jackson ImmunoResearch), 
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